Plain-English translation of NCT06964113 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ulcerative Colitis research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing filgotinib, a medication taken by mouth once daily, to see if it can help people with moderate to severe ulcerative colitis go into remission (when symptoms improve significantly or disappear). The study will track how well this treatment works and monitor its safety over 10 to 22 weeks.
Some people with ulcerative colitis don't respond well enough to current treatments, or their bodies stop responding over time. This medication is being studied to give patients another option for controlling their disease.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth once daily for up to 22 weeks. During this time, you'll have clinic visits to check how you're responding, including blood tests and possibly scope examinations to look inside your colon. The study team will track whether your symptoms improve and watch for any side effects.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
South Korea